Gurbakhash Kaur
@GKaurMD
Followers
1K
Following
15K
Media
162
Statuses
5K
Multiple Myeloma/CAR-T Specialist at Mount Sinai Hospital | Montefiore & Tufts Alum | #CAR-T #immunotherapy | Views not representative of my employer.
New York City, New York
Joined April 2009
Our multicenter series shows bispecific antibodies may offer meaningful CNS activity with manageable safety. Led by fellow Alex N! @MeeraMohanMD @HadidiSamer
https://t.co/Au5P6ee8Um
#CNSMyeloma #mmsm @RutgersCancer @RWJBarnabas
onlinelibrary.wiley.com
Click on the article title to read more.
4
16
52
Excellently written @ASCO Daily News article by @bdermanmd about nuances of MRD in myeloma #MMsm. Including clearest explanation of surrogate threshold effects I’ve seen - what ‘voltage’ of ∆ MRD neg is needed to predict ∆ PFS/OS? Hopefully MRD-guided approvals coming soon!
You are not alone in wondering what are the implications of the FDA ODAC vote last year on MRD negativity (and CR) as a surrogate endpoint for clinical trials in myeloma. I try to piece it together in this approachable primer for @ASCO daily news! Link below 👇
1
6
23
@HiraSMian Absolutely! It was inspired by several initial payor denials I received when trying to use bsabs for patients with cns involvement of multiple myeloma citing lack of data. Now we have it!
0
2
5
Happy Saturday! This weekend, catch up on the latest episodes of The HemOnc Pulse with @andrewbrunner, @GKaurMD, @DimaDanai, @LymphClinician, and many more! 🎧 https://t.co/rWvDmrl8IA
1
2
5
Very happy to have the chance to learn from nephrology colleagues from Latin America and to talk a little bit about renal disease in #myeloma and #amyloidosis. If you happen to be at the conference please stop by. #mmsm #onconephrology
0
3
10
#Myeloma Paper of the Day: Long-term follow-up of HOVON 143 trial in older NDMM pts finds higher early- & non-relapse related mortality in ultra-frail pts & pts who were frail due to impairments vs pts who were frail (by IMWG-FI) based on age alone: https://t.co/bTYdtkUy2F.
#mmsm
3
12
32
#Myeloma Paper of the Day: Iceland screens, treats, or prevents multiple myeloma (iStopMM) model shows reasonable discriminatory performance between #MGUS & myeloma in a racially and ethnically diverse Bronx population: https://t.co/lxy38rg47p.
#mmsm
2
14
31
Excellent & important #MMsm work by @nishi_shah_ @JanakiramMurali et al! Validating @iStopMM 🇮🇸 SMM prediction in the Bronx Text below ROC curve 👇 very helpful. I use iStopMM all the time to estimate % risk of >10% BMPCs. What % risk should prompt BMBx? Maybe 33% in 🇺🇸 pts!
#Myeloma Paper of the Day: Iceland screens, treats, or prevents multiple myeloma (iStopMM) model shows reasonable discriminatory performance between #MGUS & myeloma in a racially and ethnically diverse Bronx population: https://t.co/lxy38rg47p.
#mmsm
0
5
23
#Myeloma Paper of the Day: Study of temporal genomic dynamics finds odd chromosome trisomies in HD pts can be acquired w/ other chromosomal gains, HD comes after IgH translocation if co-occur, +1q prognostic impact depends on timing of acquisition: https://t.co/GJglmHqkLt.
#mmsm
2
6
28
Brentuximab vedotin and nivolumab for untreated patients with Hodgkin lymphoma: long-term results https://t.co/Xz7dOpmREw
#clinicaltrialsandobservations #lymphoidneoplasia
0
21
84
Predicting #MMsm decades before it happens - fascinating @BloodAdvances work by 🇬🇧 team. Not by looking for MGIP / infinitesimally small M-spikes, but by looking for abnormally low or high levels of other proteins! A few familiar faces on this list, but a few new ones too…
Dysregulated immune proteins in plasma in the UK Biobank predict multiple myeloma 12 years before clinical diagnosis https://t.co/zGTqonCMu1
#lymphoidneoplasia
1
10
20
And my final slide for #SeattleCT25 @binaytara talk about approved CAR-T therapies in #MMsm. Including an excellent paraphrased pearl of wisdom from @Rfonsi1 : CAR-T at 1st relapse in 🇺🇸 is only debated because it’s new… but maybe it should be our default frame of reference!
From paternity leave to plasma cells (for ≤ 2 hours until I have to go back to 👶 duty)… Excited to be here at @binaytara #SeattleCT25 cell therapy summit! Thanks @mshadman @KrishPatelMD @binayshah for organizing and inviting me!
3
6
28
Proud to co-author an op-ed with Dr. David Aboulafia in @seattletimes on the devastating impact of proposed federal cuts to cancer research funding. Washington is home to world-leading institutions like @fredhutch and @UW, driving discoveries that save lives far beyond our state.
1
5
14
Great to see the experience in diagnosis and managment of AL amyloidosis in my hometown Medellin in @BloodGlobalHema
https://t.co/hqk7m97WBK. 33 patients with AL Amyloidosis at a reference center, again cardiac involvement and AutoSCT were associated with OS. 1/ #mmsm
2
3
12
2
2
6
Nice to see @MadhavDhodapkar ‘s excellent twist on one of the most commonly used myeloma #MMsm graphics of all time at #SeattleCT25 @binaytara . Let’s break the paradigm of increasingly frequent / aggressive relapses with time and cure myeloma from the get-go!
1
4
15
#SeattleCT25 @binaytara My boss @MadhavDhodapkar reminding us that dara in maintenance is not (yet) required for quad-treated patients who undergo ASCT. Still very much an open question pending going trials!
0
3
7
#SeattleCT25 @binaytara pleasure to welcome @GKaurMD to Seattle to talk about what’s new with bispecific antibodies in myeloma #MMsm. Much of this work happening through the US MM Immunotherapy Consortium: age is just a number when it comes to bsAbs!
0
6
16
Implementing Talquetamab in community practice comes with challenges—but success is possible. In the final episode of the Around the Practice series, “Bispecifics in R/R MM: Translating Evidence into Clinical Practice,” experts, @AjaiChari, @AjayNookaMD, @MMBaljevicMD, @GKaurMD,
1
1
2